Vanguard Group »

Inhibikase Therapeutics shares owned by Vanguard Group

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Vanguard Group from 13F filings

Historical chart of Vanguard Group investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Vanguard Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Vanguard Group

Quarter filed Position value Share count Share price at filing
2024-03-31 $36k 17k 2.16
2023-12-31 $104k 82k 1.27
2023-09-30 $122k 87k 1.39
2023-06-30 $319k 88k 3.61